Compare Eli Lilly And Co (LLY) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs UnitedHealth Group Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while UnitedHealth Group Inc trades at $379.3 (market cap $332.96B). The key difference: Eli Lilly And Co is far larger — about 3.1× UnitedHealth Group Inc's market cap, and UnitedHealth Group Inc pays the higher dividend (2.5%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and UnitedHealth Group Inc for 97 Days on average.
| LLY | UNH | |
|---|---|---|
Market Cap | $1.04T | $332.96B |
Volume | 3,064,878 | 7,273,749 |
Sector | Health | Health |
52-Week High | $1.28K | $436.35 |
52-Week Low | $799.57 | $259.02 |
Typical Hold Time | 93 Days | 97 Days |
Enterprise Value | $1.09T | $374.82B |
Dividend Yield | 0.59% | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
UnitedHealth Group (UNH) trades at $370.95, down 1.34% on the day, amid a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $6.38 versus $4.91 expected, and raised full-year guidance. Revenue for 2025 reached $447.57 billion, though net income margin declined to 2.69%. Analyst consensus remains strongly bullish with an 82.69% buy rating and a $470.11 price target, suggesting significant upside from current levels.
UNH presents a compelling investment case driven by earnings beats, raised 2026 outlook, and strategic initiatives like AI investment in Optum. Key risks include regulatory pressures in healthcare, volatility from Medicare Advantage plan changes, and margin compression. The stock's valuation at a P/E of 23.84 appears reasonable given growth prospects, but investors should weigh execution risks against the positive analyst sentiment and institutional backing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
